| | |
PER SHARE
|
| |
TOTAL
|
| ||||||
Public offering price
|
| | | $ | 7.50 | | | | | $ | 150,000,000 | | |
Underwriting discounts and commissions(1)
|
| | | $ | 0.45 | | | | | $ | 9,000,000 | | |
Proceeds to Iovance Biotherapeutics, Inc. before expenses
|
| | | $ | 7.05 | | | | | $ | 141,000,000 | | |
| Goldman Sachs & Co. LLC | | |
Jefferies
|
|
| | |
Page
|
| |||
Prospectus Supplement | | | | | | | |
| | | | S-ii | | | |
| | | | S-iii | | | |
| | | | S-1 | | | |
| | | | S-5 | | | |
| | | | S-7 | | | |
| | | | S-8 | | | |
| | | | S-12 | | | |
| | | | S-19 | | | |
| | | | S-19 | | | |
| | | | S-19 | | | |
| | | | S-20 | | |
| Prospectus | | | | | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 12 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 24 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 27 | | |
UNDERWRITER
|
| |
NUMBER OF
SHARES |
| |||
Goldman Sachs & Co. LLC
|
| | | | 12,000,000 | | |
Jefferies LLC
|
| | | | 8,000,000 | | |
Total
|
| | | | 20,000,000 | | |
| | |
PER SHARE
|
| |
TOTAL
|
| ||||||||||||||||||
| | |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITHOUT
OPTION TO PURCHASE ADDITIONAL SHARES |
| |
WITH
OPTION TO PURCHASE ADDITIONAL SHARES |
| ||||||||||||
Public offering price
|
| | | $ | 7.50 | | | | | $ | 7.50 | | | | | $ | 150,000,000 | | | | | $ | 172,500,000 | | |
Underwriting discounts and commissions paid by us
|
| | | $ | 0.45 | | | | | $ | 0.45 | | | | | $ | 9,000,000 | | | | | $ | 10,350,000 | | |
Proceeds to us, before expenses
|
| | | $ | 7.05 | | | | | $ | 7.05 | | | | | $ | 141,000,000 | | | | | $ | 162,150,000 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 24 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 26 | | | |
| | | | 27 | | |
Exhibit 107
CALCULATION OF FILING FEE TABLE
424(b)(5)
(Form Type)
Iovance Biotherapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type |
Title of Each Class of to be Registered |
Fee Calculation Rule |
Amount to Registered(1) |
Proposed Offering Share |
Maximum Aggregate Price |
Fee Rate |
Amount of Registration Fee(2) | |||||||||
Fees to be Paid |
Equity | Common stock, par value $0.000041666 per share | Rule 456(b) and Rule 457(r) |
23,000,000 | 7.50 | $172,500,000 | $0.00011020 | $19,009.50 | ||||||||
Fees Previously Paid |
N/A | N/A | N/A | N/A | N/A | N/A | — | N/A | ||||||||
Total Offering Amounts | — | $172,500,000 | — | $19,009.50 | ||||||||||||
Total Fees Previously Paid | — | — | — | $— | ||||||||||||
Total Fee Offsets | — | — | — | $— | ||||||||||||
Net Fee Due | — | — | — | $19,009.50 |
(1) | Includes 3,000,000 shares of Common Stock that may be purchased by the underwriters pursuant to their option to purchase additional shares of Common Stock. |
(2) | The registration fee is calculated in accordance with Rule 456(b) and Rule 457(r) of the Securities Act of 1933, as amended. This “Calculation of Filing Fee Table” shall be deemed to update the “Calculation of Filing Fee Table” in the registrants’ Registration Statements on Form S-3 (File No. 333-272718) in accordance with Rules 456(b) and 457(r) under the Securities Act of 1933, as amended. |